WO2021107013A1 - アジュバント組成物 - Google Patents

アジュバント組成物 Download PDF

Info

Publication number
WO2021107013A1
WO2021107013A1 PCT/JP2020/044027 JP2020044027W WO2021107013A1 WO 2021107013 A1 WO2021107013 A1 WO 2021107013A1 JP 2020044027 W JP2020044027 W JP 2020044027W WO 2021107013 A1 WO2021107013 A1 WO 2021107013A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
compound
adjuvant
vaccine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/044027
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
英啓 福山
亮太 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
Original Assignee
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN filed Critical RIKEN
Priority to JP2021561492A priority Critical patent/JP7754490B2/ja
Publication of WO2021107013A1 publication Critical patent/WO2021107013A1/ja
Anticipated expiration legal-status Critical
Priority to JP2025113411A priority patent/JP2025143420A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an adjuvant composition.
  • Vaccines are one of the greatest inventions in preventive medicine in the history of human health.
  • the number of patients and deaths of the ten major diseases that can be prevented by the vaccine such as measles, mumps, whooping cough, gray myelitis, rubella, smallpox, and tetanus, was recommended by the vaccine in the United States before 1980. As a result, it decreased by 92% and 98% or more.
  • Other infectious diseases, hepatitis A, acute hepatitis B, Haemophilus influenzae type b (HPV), chickenpox cases and deaths were 87% and 81 due to vaccine recommendations in the United States between 1980 and 2005. It decreased by more than%.
  • the adjuvant enhances the immune response and reduces the antigen load.
  • Aluminum salt (Alum) is the only adjuvant that has been approved for human use for 80 years.
  • Alum is the major adjuvant used in many vaccines, including diphtheria, whooping cough, tetanus, HPV, poliomyelitis and acute hepatitis B. Although this long-term adjuvant, Alum, has shown excellent results in vaccine efficacy, it has some side effects. These are arthralgia, fatigue, fever, headache, GI and myalgia, and local pain, redness, and swelling throughout the body.
  • Vitamin D3 is a biomolecule and plays an important role in the homeostasis of calcium and phosphate, and analogs such as oxalol are used in the treatment of psoriasis.
  • Patent Document 1 describes that the antibody response is enhanced when administered 1,25 (OH) 2 D 3 after vaccination with aluminum hydroxide adjuvant (Alum).
  • Al hydroxide adjuvant Alum
  • the use as adjuvants alone in place of 1,25 (OH) 2 D 3 in Alum has not been described or suggested.
  • the present invention provides a novel adjuvant composition.
  • the present inventor has discovered for the first time that a vitamin D compound has an adjuvant action, that is, it targets CD11c + cells in the epidermis and increases germinal center B cells, memory B cells and TFH cells.
  • the present invention is as follows. [1] The composition, which is an adjuvant composition containing a vitamin D compound and is not used in combination with an aluminum salt. [2] The composition of [1], wherein the vitamin D compound is active vitamin D 3 , active vitamin D 2, or a derivative thereof. [3] The composition of [1], wherein the vitamin D compound is maxacalcitol. [4] The composition of [1], which is for intradermal administration or nasal administration.
  • a method for stimulating an immune response in a subject which comprises administering a vitamin D compound to a subject who has not been administered an aluminum salt as an adjuvant.
  • the method of [9] wherein the vitamin D compound is active vitamin D 3 , active vitamin D 2, or a derivative thereof.
  • the adjuvant composition of the present invention can enhance the immunogenicity of the vaccine.
  • Transdermal application of oxalol protects against death from viral challenge. After vaccination under different conditions, mice vaccinated with the H1N1 A / California / 04/2009 strain were infected with the same type of virus. The survival rate was shown. The number of individuals is 5 per group. Representative examples of the results of two independent experiments are shown. Transdermal application of oxalol protects against infectious diseases. After vaccination under different conditions, mice vaccinated with the H1N1 A / California / 04/2009 strain were infected with the same type of virus. It showed a change in body weight. The number of individuals is 5 per group. Representative examples of the results of two independent experiments are shown. Transdermal application of oxalol enhances the recall liquid response.
  • influenza vaccine antigen was injected intraperitoneally without adjuvant for boosting.
  • Antigen-specific memory B cells expand after oxalol-assisted immunization. After hapten immunization under different conditions, the number of hapten-positive IgG1 + CD38 + GL7 - B cells in the auricular lymph nodes was determined by total lymphocyte counts and flocymetry analysis in the auricular lymph nodes.
  • Follicular T cells expand after immunization adjuvanted with oxalol.
  • CD4 + CXCR5 + PD-1 + FoxP in auricular lymph node - the number of TFH cells was determined by counting and flow cytometry analysis of total lymphocytes in auricular lymph nodes.
  • Antigen-specific GCB cells proliferated after oxalol adjuvant immunization.
  • total lymphocytes in the auricular lymph nodes were counted and flow cytometric analysis was performed to determine the number of hapten-positive CD38- GL7 + B cells in the auricular lymph nodes.
  • Vdr expression in keratinocytes for germinal center B cell proliferation Conditional Vdr knockout mice or Cre- littermates driven by hLangerin-Cre, CD11c-Cre, K5-Cre were immunized with NP-CGG / Oxarol on the skin of the ears. The total number of NIP + CD38 - GL7 + B220 + cells in the auricular lymph nodes is shown. Decreased serum anti-NP antibody titer in K5-Vdr cKO mice.
  • Anti-NP IgG1 titers were measured by ELISA at the time indicated.
  • NP 30 and NP 0.43 as hapten antigens were used to detect low and high affinity anti-NP antibodies, respectively.
  • the vitamin D compound is a kind of vitamin, which is a fat-soluble steroid derivative secosteroid, which is similar to natural vitamin D2 and natural vitamin D3 having different side chain structures, and artificially synthesized vitamins which can be active vitamins.
  • the vitamin D compound of the present invention is preferably active vitamin D 3 , active vitamin D 2 , or a derivative thereof, and more preferably oxalol.
  • the adjuvant refers to a substance used to enhance the immunogenicity of a vaccine. More preferably, it refers to a substance that is injected with a vaccine and used to enhance its immunogenicity.
  • any conventionally known administration system can be used. Intradermal or nasal administration is preferred.
  • the aluminum salt refers to a mixture containing AlOOH, Al (OH) 3 , AlPO 4 , AlK (SO 4 ) 2 ⁇ 12H 2 O and the like, which contains a trivalent aluminum salt.
  • the aluminum salt of the present invention preferably an aluminum salt containing Al (OH) 3 , is more preferably Imject® Alum.
  • composition of the present invention may be further formulated with a pharmaceutically acceptable carrier.
  • “Pharmaceutically acceptable” has the meaning commonly used in the pharmaceutical industry and, in some cases, a molecular entity or composition that does not cause an allergic or similar adverse reaction when administered to humans. Etc. can be used.
  • the preparation of aqueous compositions containing a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injections, in liquid solutions or suspensions, and solid dosage forms suitable for dissolution or suspension in liquid prior to injection can also be prepared. The preparation can also be emulsified.
  • Carriers include any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption retarders, buffers, carrier solutions, suspensions, colloids, etc. be able to.
  • Carriers include buffers of phosphates, citrates, and other organic acid salts; antioxidants containing ascorbic acid; low molecular weight (less than about 10 amino acid residues) polypeptides; proteins (eg serum albumin, gelatin, etc.) Or immunoglobulins); hydrophobic polymers (eg polyvinylpyrrolidone); amino acids (eg glycine, glutamine, asparagine, arginine or lysine); monosaccharides, disaccharides and other carbohydrates including glucose, mannitol or dextran; chelates such as EDTA Agents; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants (eg, polyoxyalkylenes).
  • antioxidants containing ascorbic acid eglycine, glutamine, asparagine, arginine or lysine
  • monosaccharides, disaccharides and other carbohydrates including glucose,
  • composition of the present invention can contain various surfactants used in the formulation.
  • the type of the surfactant is not particularly limited, and a nonionic surfactant, a cationic surfactant, an anionic surfactant, or an amphoteric surfactant can be mentioned.
  • NP-CGG was produced by binding 4-hydroxy-3-nitrophenylacetic acid active ester to chicken gamma globulin (Rockland) (LGC biosearch technology).
  • the adjuvant Oxalol ointment and Imject® Alum adjuvant were purchased from Chugai and Thermo Fisher Scientific, respectively. An ointment containing 2.5 ⁇ g maxacalcitol or a solution containing 2.5 ⁇ g aluminum hydroxide was administered to the ears of mice.
  • Influenza Infection Study 50 ⁇ L (2 x LD 50 ) of influenza H1N1 A / California / 04/2009 virus solution was intranasally administered to mice under anesthesia, followed by body weight and survival monitoring for 14 days.
  • the Foxp3 intracellular staining kit (Catalog 88-8824-00) was purchased from eBioscience. Staining with various antibodies including NIP (4-hydroxy-3-iodo-5-nitrophenylacetic acid) -APC (self-made). Dead cells were stained with 7-aminoactinomycin D (7-AAD) and excluded. Stained cells were analyzed using FACSCanto® II (BD bioscience). Data were analyzed using FlowJo® software (FlowJo, LLC).
  • Enzyme-linked immunosorbent assay A 96-well ELISA plate (Thermo Scientific) was coated with an antigen solution in PBS at a concentration of 1 ⁇ g / mL for the H1N1 A / California / 04/2009 split vaccine. After antigen binding, non-specific binding was blocked using Blocking One (Nacalai Tesque). A serially diluted serum sample and standard serum were then added, followed by a goat anti-mouse IgG1 antibody (Southern Biotech) conjugated to HRP. The antibody titer of each serum sample was calculated based on the standard curve.
  • mice C57BL / 6JJcl mice were presented by CLEA Japan, Inc. I bought from. Vdr-floxed mice, hLangerin-Cre BAC transgenic mice, K5-Cre transgenic mice, B6. Cg-Tg (Itgax-Cre) 1-1Reiz / J (Cd11c-Cre) transgenic mice were used in this study. All animal experiments were performed using a protocol approved by RIKEN IMS Instrumental Animal Care.
  • RNA-sequencing TRIzol TM reagent was used to extract RNA from the skin of the mouse ear.
  • a cDNA library was generated using the NEBNext Ultra RNA Library Preparation Kit (NEB) for Illumina. Sequencing was performed on a HiSeq 2500 sequencer (Illumina) in 50 bp single-ended read mode. Sequencing reads were trimmed for adapter sequences, masked for low complexity or low quality sequences, and mapped to the reference genome (mm9) using Bowtie2v2.1.0 and TopHat2v2.0.8. The amount of transcript was estimated using Cufflinks v2.1.1 as an FPKM (fragment per kilobase of mapped exon million fragments) value.
  • the adjuvant composition of the present invention is useful for enhancing the immunogenicity of a vaccine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2020/044027 2019-11-29 2020-11-26 アジュバント組成物 Ceased WO2021107013A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021561492A JP7754490B2 (ja) 2019-11-29 2020-11-26 アジュバント組成物
JP2025113411A JP2025143420A (ja) 2019-11-29 2025-07-04 アジュバント組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019216835 2019-11-29
JP2019-216835 2019-11-29

Publications (1)

Publication Number Publication Date
WO2021107013A1 true WO2021107013A1 (ja) 2021-06-03

Family

ID=76129420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/044027 Ceased WO2021107013A1 (ja) 2019-11-29 2020-11-26 アジュバント組成物

Country Status (2)

Country Link
JP (2) JP7754490B2 (https=)
WO (1) WO2021107013A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11512297A (ja) * 1995-09-19 1999-10-26 ファーマダイム・インコーポレイテッド 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるｄｎａ構築物
JP2002536339A (ja) * 1999-02-02 2002-10-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細菌毒性におけるｄｎａメチル化の必須な役割に基づいて病原性細菌感染を処置および予防するための組成物および方法
JP2010539918A (ja) * 2007-09-26 2010-12-24 サノフィ・パスツール インフルエンザウイルスの製造方法
JP2012246259A (ja) * 2011-05-30 2012-12-13 Japan Health Science Foundation Ｈ５ｎ１型インフルエンザワクチン及び感染防御キット
US20130011437A1 (en) * 2011-07-05 2013-01-10 Life Spring Immuno Science Corp. Immune compositions for treating H. pylori infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11512297A (ja) * 1995-09-19 1999-10-26 ファーマダイム・インコーポレイテッド 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるｄｎａ構築物
JP2002536339A (ja) * 1999-02-02 2002-10-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細菌毒性におけるｄｎａメチル化の必須な役割に基づいて病原性細菌感染を処置および予防するための組成物および方法
JP2010539918A (ja) * 2007-09-26 2010-12-24 サノフィ・パスツール インフルエンザウイルスの製造方法
JP2012246259A (ja) * 2011-05-30 2012-12-13 Japan Health Science Foundation Ｈ５ｎ１型インフルエンザワクチン及び感染防御キット
US20130011437A1 (en) * 2011-07-05 2013-01-10 Life Spring Immuno Science Corp. Immune compositions for treating H. pylori infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIKAWA, FUMIHIKO ET AL: "Explanation of medicine Maxacalcitol", vol. 39, no. 10, 2003, pages 967 - 969 *
SATO R. ET AL.: "Repurposing the psoriasis drug Oxarol to an ointment adjuvant for the influenza vaccine", INT. IMMUNOL., vol. 32, no. 8, February 2020 (2020-02-01), pages 499 - 507, XP055832407 *

Also Published As

Publication number Publication date
JPWO2021107013A1 (https=) 2021-06-03
JP2025143420A (ja) 2025-10-01
JP7754490B2 (ja) 2025-10-15

Similar Documents

Publication Publication Date Title
Coccia et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
TW202144383A (zh) 冠狀病毒免疫原性組合物及其等之用途
Reed et al. Deficiency of autophagy protein Map1-LC3b mediates IL-17-dependent lung pathology during respiratory viral infection via ER stress-associated IL-1
JP3530526B2 (ja) ＨＳＶ糖蛋白質ｇＤおよび３脱アシル化モノホスホリルリピッドＡからなる単純ヘルペスワクチン
CA2946511C (en) Compositions and methods for treating cytokine-related disorders
JP6629195B2 (ja) ウイルス免疫療法用の医薬組成物およびその使用
JPH07504683A (ja) Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用
CN110198736B (zh) 带状疱疹疫苗组合物
CN101489589A (zh) 免疫原性组合物
WO2017122635A1 (ja) 固定化ウイルス粒子を含むワクチン
Litinsky et al. Vaccination against influenza in patients with systemic sclerosis
JP4875494B2 (ja) 免疫調節物質
US11771759B2 (en) Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
JP7754490B2 (ja) アジュバント組成物
Yang et al. Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection
US20210338575A1 (en) Dry pharmaceutical composition for inhalation
EP2822595B1 (en) Sphingosine-1 -phosphate receptors modulators for improving vaccine immunization
JPWO2009001673A1 (ja) Ａｔｐ含有免疫アジュバント
US11491197B2 (en) Multiple viral antigen COVID vaccine and therapeutic
Diego et al. A combination TLR7/8 and RIG-I agonist adjuvant reverts asthmatic allergic sensitization and prevents aggravated influenza infection in OVA-sensitized mice
WO2026080609A1 (en) Compositions and methods for degradation-enhanced immunotherapies
TW202428287A (zh) 包含類鐸受體促效劑及干擾素基因刺激劑之促效劑的醫藥組成物及其用途
WO2024084785A1 (ja) Ｒｓウイルスワクチンとしての利用に好適な組成物
Schotsaert et al. Muscle Injury and Aging Differentially Shape Immune Responses to Influenza Vaccination
CN117042776A (zh) 疫苗佐剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20894148

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021561492

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20894148

Country of ref document: EP

Kind code of ref document: A1